Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

E-ISSN： 1873-5576|11|3|254-284

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.11, Iss.3, 2011-03, pp. : 254-284

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Dual Transporter Inhibitor Duloxetine: A Review of its Preclinical Pharmacology, Pharmacokinetic Profile, and Clinical Results in Depression

Current Pharmaceutical Design, Vol. 11, Iss. 12, 2005-05 ,pp. : 1475-1493

Bentham Science Publishers

Access to resources Recommend Favorite

Electroporation Gene Therapy Preclinical and Clinical Trials for Melanoma

Current Gene Therapy, Vol. 10, Iss. 4, 2010-08 ,pp. : 312-317

Bentham Science Publishers

Access to resources Recommend Favorite

Selection of natural health products for clinical trials: a preclinical template

By Vohra S. Adams D. Hudson J.B. Moore J.A. Vimalanathan S. Sharma M. Burt A.J. Lamont E. Lacaze N. Arnason J.T. Lee T.D.G.

Canadian Journal of Physiology and Pharmacology, Vol. 87, Iss. 5, 2009-05 ,pp. : 371-378

NRC Research Press

Access to resources Recommend Favorite

From Preclinical to Clinical Trials: An Update on Potential Therapies for Huntington’s Disease

By S. Brocardo Patricia M. Gil-Mohapel Joana

Current Psychopharmacology, Vol. 2, Iss. 2, 2013-05 ,pp. : 113-131

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Targeting of TRPV1 by Resiniferatoxin, from Preclinical Studies to Clinical Trials

Current Topics in Medicinal Chemistry, Vol. 11, Iss. 17, 2011-09 ,pp. : 2159-2170

Bentham Science Publishers

Access to resources Recommend Favorite